Serum Malondialdehyde Levels In Patients Research Articles

Serum Malondialdehyde Levels in Patients with Non Alcoholic Fatty Liver Disease

Serum Malondialdehyde Levels in Patients with Non Alcoholic Fatty Liver Disease

Assessment of lipid peroxidation status in the serum of Moroccan patients with nasopharyngeal carcinoma

Many studies have addressed the role of oxidative stress products in the carcinogenesis of nasopharyngeal carcinoma (NPC). The current study aimed to assess malondialdehyde (MDA) levels in the serum of patients with NPC before and after chemo- radiotherapy (CRT), to evaluate its potential role as a biomarker in the management of this disease. A total of 112 patients with newly diagnosed NPC, occurring between January 2017 and February 2019, were enrolled and followed up. The level of MDA was determined by spectrophotometric method. Serum MDA levels in NPC patients before CRT were higher (0.911 µmol/ml/mg) than that obtained in the control group (0.613 µmol/ml/mg) (p < 0.00). After CRT, MDA levels decreased significantly (0.698 µmol/ml/mg) (p = 0.007). Serum MDA levels in patients at advanced disease stages (III-IV) were significantly higher (0.966 µmol/ml/mg) than those at early disease stage (I-II) (0.492 µmol/ml/mg) (p = 0.001). Additionally, no significant association was observed between MDA levels before CRT and patients' outcomes (p > 0.05). In conclusion, high levels of MDA in the serum of patients with NPC before CRT, and their increase with disease stage, accurately reflect the heightened oxidative stress level in NPC. These findings strongly imply that MDA serum levels could be used as a biomarker in the progression monitoring of NPC.

Variations in serum malondialdehyde levels in patients with leukemia

Leukemias are malignant neoplasms of hematopoietic stem cells characterized by diffuse infiltration of the blood and bone marrow by neoplastic cells. Leukemias are classified as acute and chronic according to clinical course and myeloid and lymphoid according to the cell predominantly involved in leukemic process. Free radicals are implicated in the pathogenesis of leukemia. Oxidative destruction of polyunsaturated fatty acid is called as lipid peroxidation. In this study, we determined serum malonyldialdehyde (MDA) level as a lipid peroxidation product in patients with leukemia. The mean serum MDA levels were significantly increased in leukemic patients (psignificant difference in serum MDA levels with respect to sex only in patients with chronic myeloid leukemia. Whereas in age groups, we found significant trend in serum MDA levels in patients with CML, AML and ALL patients. There was no significant difference in serum MDA level in patients with CLL with respect to age. Our finding of the high levels of serum malondialdehyde in leukemic patients as compared to healthy control may be due to increased oxidative stress in patients with leukemia. Keywords: Malondialdehyde, Leukemia, Oxidative stress

Serum malondialdehyde (MDA) level as a potential biomarker of cancer progression for patients with bladder cancer.

Bladder cancer is the most common malignancy involving the urinary system. Recent research tends to emphasize the role of oxidative stress products in the carcinogenesis of bladder cancer. The level of oxidative stress can be measured by assessing the MDA levels. This study aimed to evaluate serum MDA levels in patients with bladder cancer, as well as to determine its potential role as a biomarker in the diagnosis of the disease and progression risk considerations. The study was designed as a cross-sectional study and included 90 patients, divided into three groups with 30 patients each: Ta, T1and T2-T4 group, based on histopathological findings after transurethral resection of the tumor. The control group included 30 healthy volunteers. MDA level was determined using the spectrophotometric method. Serum MDA level in patients with bladder cancer [0.86 (0.78-1.05) μmol/L] was significantly higher than the serum MDA level in control group [0.70 (0.69-0.72) μmol/L] (p < 0.001). Serum MDA level in Ta group [0.73 (0.70-1.05) μmol/L], T1 group [0.85 (0.80-1.12) μmol/L] and in T2-T4 group [0.91 (0.84-1.04) μmol/L] was significantly higher than the serum MDA level in control group [0.70 (0.69-0.72) μmol/L] (p < 0.01). MDA level in T1 and T2-T4 group was significantly higher than the MDA level in Ta group (p < 0.01). No significant difference was observed in MDA level between T1 and T2-T4 group (p = NS). A statistically significant positive correlation was found between tumor size and serum MDA level in patients with bladder cancer (rho = 0.254 p < 0.01). The results of the present study suggest that MDA serum level might play a significant role as a biomarker in the diagnosis of bladder cancer, as well as in the monitoring of its progression.

Role of antioxidants as a stress factor for potentially malignant, malignant disorders and healthy individuals: A correlative study

Background: The possible role of free radicals in pathogenesis of a disease and its prevention by antioxidants is well-known. Literature reveals an independent correlation between the risk factors and these disorders. The aim of the present study was to ascertain the values of vitamin A, vitamin E, superoxide dismutase (SOD), and malondialdehyde (MDA) in normal individuals and patients with potentially malignant and malignant disorders. Materials and Methods: In this study, serum vitamin A, E, SOD, and MDA levels were assessed in 80 patients divided into four groups marked as a group I normal individuals, group IIa individuals with habits but without any lesions, group IIb with potentially malignant disorders, and group III with malignant disorders. Results: The mean vitamin A level in the group I was 3.07 ± 0.27, group IIa was 1.48 ± 0.37, group IIb was 0.89 ± 0.21, and group III was 0.67 ± 0.17. The mean vitamin E level in group I was 9.89 ± 0.75, group IIa was 8.85 ± 0.42, group IIb was 7.63 ± 0.39, and group III was 6.43 ± 0.34. The mean MDA level in group I was 2.92 ± 0.36, group IIa was 6.05 ± 0.78, group IIb was 10.13 ± 0.75, and group III was 14.15 ± 0.47. The mean SOD activity level among group I was 189.45 ± 14.17, group IIa was 169.05 ± 4.98, group IIb was 115.65 ± 19.60, and group III was 52.63 ± 4.02. Conclusion: There was a significant reduction in serum Vitamin A, Vitamin E, and SOD levels whereas there was a significant increase in serum MDA levels in patients with potentially malignant and malignant disorders as compared to normal individuals.

Serum malondialdehyde levels in patients with malignant middle cerebral artery infarction are associated with mortality.

ObjectiveMalondialdehyde (MDA) is an end-product formed during lipid peroxidation, due to degradation of cellular membrane phospholipids. MDA is released into extracellular space and finally into the blood; it has been used as an effective biomarker of lipid oxidation. High circulating levels of MDA have been previously described in patients with ischemic stoke than in controls, and an association between circulating MDA levels and neurological functional outcome in patients with ischemic stoke. However, an association between serum MDA levels and mortality in patients with ischemic stroke has not been previously reported, and that was the objective of this study.MethodsObservational, prospective and multicenter study performed in six Intensive Care Units. We included patients with severe malignant middle cerebral artery infarction (MMCAI) defined as Glasgow Coma Scale (GCS) lower than 9. We measured serum MDA levels in 50 patients with severe MMCAI at the time of diagnosis and in 100 healthy subjects. Mortality at 30 days was the end point of the study.ResultsWe found that patients with severe MMCAI showed higher serum MDA levels than healthy subjects (p<0.001). We found higher serum MDA levels (p<0.001) in non-surviving MMCAI patients (n=26) than in survivors (n=24). The area under the curve for prediction of 30-day mortality for serum MDA levels was 0.77 (95% CI = 0.63-0.88; p<0.001). Serum MDA levels >2.27 nmol/mL were associated with 30-day mortality (OR=7.23; 95% CI=1.84-28.73; p=0.005) controlling for GCS and age on multiple binomial logistic regression analysis.ConclusionsTo our knowledge, this is the first study showing that serum malondialdehyde levels in patients with MMCAI are associated with early mortality.

Association between serum malondialdehyde levels and mortality in patients with severe brain trauma injury.

There is a hyperoxidative state in patients with trauma brain injury (TBI). Malondialdehyde (MDA) is an end-product formed during oxidative stress, concretely lipid peroxidation. In small studies (highest sample size 50 patients), higher levels of MDA have been found in nonsurviving than surviving patients with TBI. An association between serum MDA levels and mortality in patients with TBI, however, has not been reported. Thus, the objective of this prospective, observational, multicenter study, performed in six Spanish intensive care units, was to determine whether MDA serum levels are associated with early mortality in a large series of patients with severe TBI. Serum MDA levels were measured in 100 patients with severe TBI on day 1 and in 75 healthy controls. The end-point of the study was 30-day mortality. We found higher serum MDA levels in patients with severe TBI than in healthy controls (p < 0.001). Nonsurviving patients with TBI (n = 27) showed higher serum MDA levels (p < 0.001) than survivors (n = 73). Logistic regression analysis showed that serum MDA levels were associated with 30-day mortality (odds ratio [OR] = 4.662; 95% confidence interval [CI] = 1.466-14.824; p = 0.01), controlling for Glasgow Coma Score, age, and computed tomography findings. Survival analysis showed that patients with serum MDA levels higher than 1.96 nmol/mL presented increased 30-day mortality than patients with lower levels (hazard ratio = 3.5; 95% CI = 1.43-8.47; p < 0.001). Thus, the most relevant new finding of our study, the largest to date on serum MDA levels in patients with severe TBI, was an association between serum MDA levels and early mortality.

Increased Serum Malondialdehyde Levels in Chronic Stage of Ischemic Stroke

Serum lipoperoxidation products such as malondialdehyde (MDA) reflect oxidative stress. There are contradictory results addressing the levels of lipoperoxidation products in chronic phase of ischemic stroke. In the present study, we aimed to determine the serum MDA levels in stroke patients 6 months after the cerebrovascular accident. We also compared serum MDA levels in two major groups of patients with ischemic stroke resulting from small vessel and large vessel diseases, respectively. Serum MDA levels of thirty-eight patients who had ischemic stroke (19 with atherothrombotic ischemic stroke and 19 with lacunar infarction) and 30 healthy volunteers were measured. While there was no significant difference in serum MDA levels between the chronic ischemic stroke subgroups (p = 0.795), the serum MDA levels of patients with atherothrombotic ischemic stroke (p < 0.001) or with lacunar infarction (p < 0.001) were significantly higher compared to the control group. We also demonstrated that serum MDA levels of the patients with and those without hypertension (p = 0.846), diabetes mellitus (p = 0.891), or dyslipidemia (p = 0.38) were not significantly different. In conclusion, serum MDA levels were elevated in chronic stroke patients with small or large vessel diseases. To the best of our knowledge, this is the first report showing that serum MDA levels of these two groups are not significantly different. Furthermore, serum MDA levels do not differ solely by the existence or nonexistence of hypertension, diabetes mellitus or hyperlipidemia.

Cerebrospinal fluid superoxide dismutase and serum malondialdehyde levels in patients with aneurysmal subarachnoid hemorrhage: preliminary results

Objectives: Experimental studies provide evidence that oxidative damage plays a role in the development of vasospasm after aneurysmal subarachnoid hemorrhage (SAH) but data from human studies is still limited. The purpose of this study was to investigate the time course of cerebrospinal fluid (CSF) superoxide dismutase (SOD) and serum malondialdehyde (MDA) changes in patients with aneurysmal SAH.Methods: SOD in CSF and MDA in the serum were detected on days 1–3, 5 and 7 after aneurysmal SAH in 21 patients, and the results were compared with 15 patients with hydrocephalus. The results were also compared with those of clinical parameters including the patient's outcome at 6 months.Results: The mean CSF SOD levels were lower and serum MDA levels were higher than the controls. Patients with a high amount of blood within the cisterns had a trend to decreased SOD while increasing MDA levels.Conclusion: These preliminary results suggest that the levels of antioxidants are decreased after the onset of SAH in the early period, possibly because of increased oxidative stress. Reactive oxygen-mediated oxidative damage may play an important role in inflammation after SAH.